دورية أكاديمية
Therapeutic vulnerabilities of cancer stem cells and effects of natural products.
| العنوان: | Therapeutic vulnerabilities of cancer stem cells and effects of natural products. |
|---|---|
| المؤلفون: | Reisenauer KN; Department of Biology, Baylor University, Waco, TX, USA. Joseph_Taube@baylor.edu., Aroujo J; Department of Chemistry and Biochemistry, Baylor Univesrity, Waco, TX, USA., Tao Y; Department of Chemistry and Biochemistry, Baylor Univesrity, Waco, TX, USA., Ranganathan S; Department of Biology, Baylor University, Waco, TX, USA. Joseph_Taube@baylor.edu., Romo D; Department of Chemistry and Biochemistry, Baylor Univesrity, Waco, TX, USA., Taube JH; Department of Biology, Baylor University, Waco, TX, USA. Joseph_Taube@baylor.edu.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA. |
| المصدر: | Natural product reports [Nat Prod Rep] 2023 Aug 16; Vol. 40 (8), pp. 1432-1456. Date of Electronic Publication: 2023 Aug 16. |
| نوع المنشور: | Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Royal Society of Chemistry Country of Publication: England NLM ID: 8502408 Publication Model: Electronic Cited Medium: Internet ISSN: 1460-4752 (Electronic) Linking ISSN: 02650568 NLM ISO Abbreviation: Nat Prod Rep Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [London, England] : Royal Society of Chemistry, c1984- |
| مواضيع طبية MeSH: | Neoplasms*/drug therapy , Neoplasms*/pathology, Humans ; Neoplastic Stem Cells |
| مستخلص: | Covering: 1995 to 2022Tumors possess both genetic and phenotypic heterogeneity leading to the survival of subpopulations post-treatment. The term cancer stem cells (CSCs) describes a subpopulation that is resistant to many types of chemotherapy and which also possess enhanced migratory and anchorage-independent growth capabilities. These cells are enriched in residual tumor material post-treatment and can serve as the seed for future tumor re-growth, at both primary and metastatic sites. Elimination of CSCs is a key goal in enhancing cancer treatment and may be aided by application of natural products in conjunction with conventional treatments. In this review, we highlight molecular features of CSCs and discuss synthesis, structure-activity relationships, derivatization, and effects of six natural products with anti-CSC activity. |
| References: | Stem Cell Res Ther. 2013;4(6):146. (PMID: 24331293) Nat Rev Drug Discov. 2012 Apr 13;11(5):384-400. (PMID: 22498752) Free Radic Biol Med. 2010 Mar 1;48(5):713-26. (PMID: 20036734) Org Lett. 2022 Sep 16;24(36):6499-6504. (PMID: 35944279) Molecules. 2019 Nov 30;24(23):. (PMID: 31801262) Science. 2009 Oct 23;326(5952):572-4. (PMID: 19726788) Oncol Lett. 2020 Sep;20(3):2506-2515. (PMID: 32782570) Appl Biochem Biotechnol. 2015 Aug;176(7):1996-2017. (PMID: 26113217) Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14376-81. (PMID: 11121041) Int J Oncol. 2014 Mar;44(3):693-9. (PMID: 24365974) Front Cell Dev Biol. 2020 Apr 24;8:283. (PMID: 32391363) Cell Cycle. 2011 Jun 15;10(12):2008-16. (PMID: 21558812) Sci Rep. 2015 Nov 10;5:16222. (PMID: 26552848) Indian J Med Res. 1995 Jan;101:31-5. (PMID: 7883281) Pancreas. 2004 May;28(4):e90-5. (PMID: 15097869) Ann Intern Med. 2006 Mar 7;144(5):337-43. (PMID: 16520474) Nat Prod Res. 2022 Mar;36(5):1143-1150. (PMID: 33342291) Int J Oncol. 2016 Jan;48(1):385-98. (PMID: 26648459) Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7301-E7310. (PMID: 28811376) J Pharm Pharmacol. 1997 Jan;49(1):105-7. (PMID: 9120760) Cell. 2008 May 16;133(4):704-15. (PMID: 18485877) J Med Chem. 1980 Oct;23(10):1134-6. (PMID: 6893469) Exp Ther Med. 2018 Aug;16(2):1266-1272. (PMID: 30116377) J Cell Physiol. 2019 Aug;234(10):18448-18458. (PMID: 30908631) Int J Oncol. 2016 Sep;49(3):1019-27. (PMID: 27573203) Clin Cancer Res. 2009 Dec 15;15(24):7593-7601. (PMID: 19996211) Cell Physiol Biochem. 2018;51(4):1518-1532. (PMID: 30497079) J Clin Pharmacol. 2002 Oct;42(10):1122-33. (PMID: 12362927) Biomaterials. 2012 Jan;33(2):679-91. (PMID: 22019123) Angew Chem Int Ed Engl. 2011 Sep 26;50(40):9452-5. (PMID: 21915975) Biochem Biophys Res Commun. 2017 Oct 21;492(3):373-378. (PMID: 28847725) J Natl Cancer Inst. 2010 May 5;102(9):638-49. (PMID: 20339138) Clin Cancer Res. 2015 May 1;21(9):2084-95. (PMID: 25934888) Cell Stem Cell. 2010 Sep 3;7(3):279-82. (PMID: 20804964) J Exp Clin Cancer Res. 2020 Oct 7;39(1):208. (PMID: 33028364) Brain. 2015 Sep;138(Pt 9):2553-70. (PMID: 26121981) Cancer Res. 1990 May 1;50(9):2618-24. (PMID: 2158395) J Cell Biochem. 2019 Jan;120(1):622-633. (PMID: 30596403) Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63. (PMID: 17548814) Blood. 2010 Nov 4;116(18):3593-603. (PMID: 20644115) Toxicol Lett. 2013 Oct 24;222(2):139-45. (PMID: 23916687) Trends Mol Med. 2010 Mar;16(3):107-21. (PMID: 20167536) Ann Surg Oncol. 2012 Jul;19 Suppl 3:S539-48. (PMID: 21879266) Planta Med. 1983 Nov;49(3):185-7. (PMID: 6657788) Molecules. 2015 Feb 05;20(2):2728-69. (PMID: 25665066) Cancer Lett. 2004 Jan 8;203(1):59-69. (PMID: 14670618) J Mater Chem B. 2019 Mar 28;7(12):2054-2062. (PMID: 32254809) J Endocrinol. 1995 Nov;147(2):295-302. (PMID: 7490559) Nat Rev Mol Cell Biol. 2019 Oct;20(10):642-657. (PMID: 31350521) Nat Struct Mol Biol. 2009 Mar;16(3):304-311. (PMID: 19234465) Eur J Med Chem. 2010 Feb;45(2):705-9. (PMID: 19945197) Mol Cancer Ther. 2003 Dec;2(12):1361-8. (PMID: 14707277) Oncol Lett. 2013 May;5(5):1719-1723. (PMID: 23761839) Oncogene. 2016 Oct 6;35(40):5248-5262. (PMID: 26973241) Ann Surg Oncol. 2011 Jun;18(6):1797-804. (PMID: 21267784) Sci Rep. 2016 Feb 03;6:18074. (PMID: 26838463) Arch Dermatol Res. 2013 Jan;305(1):35-47. (PMID: 22740085) J Org Chem. 2011 Sep 16;76(18):7497-509. (PMID: 21838266) AAPS J. 2015 Nov;17(6):1341-56. (PMID: 26335307) Exp Ther Med. 2015 Feb;9(2):289-293. (PMID: 25574188) Cancer Res. 2005 Oct 1;65(19):9064-72. (PMID: 16204081) Biochim Biophys Acta. 2014 Aug;1839(8):702-10. (PMID: 24583552) Mol Cancer Ther. 2015 Aug;14(8):1824-36. (PMID: 26078298) Science. 2003 Apr 25;300(5619):615-8. (PMID: 12714738) Int J Cancer. 2021 Jun 15;148(12):2884-2897. (PMID: 33197277) Sci Rep. 2021 May 20;11(1):10652. (PMID: 34017048) Prostate. 1993;22(4):335-45. (PMID: 8497428) J Med Chem. 2007 Dec 13;50(25):6405-10. (PMID: 17990847) PLoS One. 2014 Jan 29;9(1):e87409. (PMID: 24489910) Chemistry. 2017 Feb 10;23(9):2077-2083. (PMID: 27740704) Cell. 2009 Aug 21;138(4):645-659. (PMID: 19682730) Discov Med. 2019 May;27(149):177-188. (PMID: 31361980) Oncol Lett. 2019 Sep;18(3):3081-3091. (PMID: 31452785) Front Chem. 2021 Jan 15;8:601649. (PMID: 33520933) Clin Cancer Res. 2013 Jun 15;19(12):3224-33. (PMID: 23630166) Cancer Biol Ther. 2009 Sep;8(18):1747-53. (PMID: 19738422) World J Gastroenterol. 2012 Sep 7;18(33):4618-26. (PMID: 22969238) Anticancer Agents Med Chem. 2023;23(10):1122-1144. (PMID: 35598250) Anticancer Res. 2012 Jul;32(7):2567-84. (PMID: 22753715) Mol Med Rep. 2021 Jan;23(1):. (PMID: 33179087) Cell Rep. 2015 Jan 13;10(2):131-9. (PMID: 25578726) PLoS One. 2015 Nov 03;10(11):e0141919. (PMID: 26528725) NPJ Breast Cancer. 2021 Mar 2;7(1):22. (PMID: 33654071) Cancer Res. 2010 Jun 1;70(11):4602-12. (PMID: 20460510) Biochem Biophys Res Commun. 2016 Nov 18;480(3):415-421. (PMID: 27771251) PLoS One. 2016 Feb 09;11(2):e0148807. (PMID: 26859746) Oncotarget. 2017 Jul 10;8(39):65548-65565. (PMID: 29029452) Antimicrob Agents Chemother. 1979 Mar;15(3):361-7. (PMID: 464561) Int J Pharm. 2011 Sep 15;416(1):331-8. (PMID: 21729743) Oncogene. 2006 Jan 12;25(2):278-87. (PMID: 16170359) Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8. (PMID: 12629218) Med Res Rev. 2015 Sep;35(5):937-67. (PMID: 25850821) Nat Rev Drug Discov. 2009 Sep;8(9):724-32. (PMID: 19721445) Molecules. 2021 Feb 18;26(4):. (PMID: 33670440) Cancer Cell Int. 2015 Oct 09;15:96. (PMID: 26457069) Free Radic Biol Med. 2015 Feb;79:127-37. (PMID: 25499851) Biomed Pharmacother. 2017 Oct;94:974-981. (PMID: 28810535) Eur J Pharmacol. 2021 Feb 15;893:173824. (PMID: 33347821) EMBO Mol Med. 2014 Aug 20;6(10):1263-78. (PMID: 25143352) J Biomed Biotechnol. 2012;2012:950658. (PMID: 23251084) Epigenetics. 2014 May;9(5):669-77. (PMID: 24589714) Cancer Causes Control. 1998 Dec;9(6):553-7. (PMID: 10189040) PLoS One. 2015 Mar 16;10(3):e0120919. (PMID: 25775405) Nature. 2007 Jan 4;445(7123):111-5. (PMID: 17122771) Neoplasia. 2004 Jul-Aug;6(4):354-63. (PMID: 15256057) Eur J Med Chem. 2010 Sep;45(9):3916-23. (PMID: 20561720) Anal Biochem. 2019 May 1;572:25-32. (PMID: 30825429) Phytother Res. 2019 Oct;33(10):2783-2791. (PMID: 31342620) J Clin Invest. 2012 May;122(5):1849-68. (PMID: 22505459) Bioorg Med Chem Lett. 2012 Dec 1;22(23):7146-50. (PMID: 23079523) Int J Oncol. 2018 May;52(5):1593-1602. (PMID: 29512729) Nat Med. 2017 Oct 6;23(10):1124-1134. (PMID: 28985214) J Cancer. 2018 Apr 6;9(8):1394-1402. (PMID: 29721049) Oncol Rep. 2014 Feb;31(2):673-8. (PMID: 24297371) Technol Cancer Res Treat. 2018 Jan 1;17:1533033818789635. (PMID: 30111255) Cell Growth Differ. 1996 Oct;7(10):1345-51. (PMID: 8891338) Toxicol Appl Pharmacol. 2020 Aug 15;401:115071. (PMID: 32454055) Eur J Med Chem. 2018 Jan 1;143:854-865. (PMID: 29223100) Nat Struct Mol Biol. 2013 Mar;20(3):311-6. (PMID: 23416945) Nat Commun. 2012 Feb 21;3:680. (PMID: 22353711) Biochim Biophys Acta. 2013 Sep;1833(9):2057-69. (PMID: 23639289) Free Radic Res. 1997 Jan;26(1):63-70. (PMID: 9018473) Nat Med. 1997 Jul;3(7):730-7. (PMID: 9212098) Indian J Pharm Sci. 2011 May;73(3):262-70. (PMID: 22457548) Cell Cycle. 2011 Nov 15;10(22):3871-85. (PMID: 22127234) Clin Cancer Res. 2012 Sep 15;18(18):5008-19. (PMID: 22806875) Cancer Cell. 2005 Oct;8(4):275-85. (PMID: 16226703) Ann Med Health Sci Res. 2012 Jul;2(2):191-8. (PMID: 23439914) Biochem Biophys Res Commun. 1988 Nov 30;157(1):183-9. (PMID: 2848517) Nat Struct Mol Biol. 2012 Jan 08;19(2):136-44. (PMID: 22231400) Exp Cell Res. 2000 Jul 10;258(1):101-8. (PMID: 10912792) Cancer Res. 1993 Mar 15;53(6):1328-31. (PMID: 8443813) Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11717-22. (PMID: 22753465) J Natl Cancer Inst. 1998 Mar 4;90(5):381-8. (PMID: 9498488) Nucleic Acids Res. 2019 Jun 4;47(10):5038-5048. (PMID: 30916320) Mol Med Rep. 2018 Feb;17(2):3397-3403. (PMID: 29257278) J Antibiot (Tokyo). 2016 Jan;69(1):31-50. (PMID: 26350782) Clinics (Sao Paulo). 2013 May;68(5):694-701. (PMID: 23778405) Mol Cell. 2014 Sep 4;55(5):758-70. (PMID: 25087875) PLoS One. 2012;7(12):e50638. (PMID: 23284640) ACS Appl Bio Mater. 2020 Oct 19;3(10):6811-6822. (PMID: 35019344) BMC Complement Altern Med. 2012 Oct 24;12:195. (PMID: 23095512) Semin Cancer Biol. 2021 Jul;72:198-213. (PMID: 32461152) Thromb Res. 1985 Nov 1;40(3):413-7. (PMID: 4082116) Trends Mol Med. 2019 Nov;25(11):993-1009. (PMID: 31230909) Appl Microbiol Biotechnol. 2004 Feb;63(6):626-34. (PMID: 14689246) Nutr Cancer. 1999;34(1):12-9. (PMID: 10453436) Nature. 2004 Nov 18;432(7015):396-401. (PMID: 15549107) Lancet Oncol. 2009 May;10(5):459-66. (PMID: 19269895) Sci Signal. 2017 Jun 13;10(483):. (PMID: 28611183) Pharmacol Ther. 2015 Jun;150:1-22. (PMID: 25578037) Endocrine. 2007 Aug;32(1):69-78. (PMID: 17992604) Cell. 1999 Oct 29;99(3):247-57. (PMID: 10555141) Oncotarget. 2017 Nov 20;8(63):106740-106752. (PMID: 29290985) Nat Cell Biol. 2011 Mar;13(3):317-23. (PMID: 21336307) J Nat Prod. 1995 Jan;58(1):74-81. (PMID: 7760080) Cancer Lett. 2008 Oct 8;269(2):226-42. (PMID: 18492603) Eur J Pharmacol. 2009 Dec 25;625(1-3):220-33. (PMID: 19836374) Science. 2016 May 27;352(6289):1078-82. (PMID: 27230373) Cancer Sci. 2016 Jan;107(1):5-11. (PMID: 26362755) Oncol Lett. 2020 Jun;19(6):4177-4182. (PMID: 32391111) Clin Dev Immunol. 2012;2012:708036. (PMID: 22693526) Br J Pharmacol. 1998 Jun;124(3):425-7. (PMID: 9647462) Cancer Res. 2014 May 1;74(9):2487-98. (PMID: 24626093) Genes Dev. 2007 Dec 15;21(24):3369-80. (PMID: 18079182) Bioorg Med Chem Lett. 2019 Apr 1;29(7):859-869. (PMID: 30765189) Annu Rev Pathol. 2016 May 23;11:47-76. (PMID: 27193450) Neurooncol Adv. 2020 Apr 27;2(1):vdaa046. (PMID: 32642699) Cell Rep. 2012 Feb 23;1(2):83-90. (PMID: 22720264) Cell Stem Cell. 2013 Apr 4;12(4):387-8. (PMID: 23561438) Antibiot Khimioter. 2004;49(6):3-5. (PMID: 15628794) Cancer Res. 2020 Jun 15;80(12):2689-2702. (PMID: 32341035) Chem Commun (Camb). 2016 Apr 14;52(29):5136-9. (PMID: 26997457) Oncol Lett. 2014 Jul;8(1):295-300. (PMID: 24959264) Nat Struct Mol Biol. 2007 Nov;14(11):1008-16. (PMID: 17984963) Asian Pac J Cancer Prev. ;18(1):3-9. (PMID: 28239999) Am J Cancer Res. 2018 Feb 01;8(2):317-331. (PMID: 29511601) Pharmacol Ther. 2015 Feb;146:1-11. (PMID: 25172549) Br J Cancer. 2012 Jan 3;106(1):99-106. (PMID: 22215106) Cell Death Differ. 2004 Oct;11(10):1066-75. (PMID: 15195070) Oncogene. 2013 Feb 21;32(8):939-46. (PMID: 23160372) Biomed Pharmacother. 2011 Oct;65(7):509-15. (PMID: 21996439) Dev Cell. 2008 Jun;14(6):818-29. (PMID: 18539112) Biochem Biophys Res Commun. 1995 Jan 17;206(2):533-40. (PMID: 7530002) Int J Cancer. 2011 Dec 1;129(11):2720-31. (PMID: 21384342) Bioorg Med Chem Lett. 2015 Oct 15;25(20):4544-8. (PMID: 26341136) Antibiot Khimioter. 2000;45(10):10-4. (PMID: 11212393) Cell Death Dis. 2014 Mar 13;5:e1112. (PMID: 24625971) Int J Biochem Cell Biol. 2000 Nov-Dec;32(11-12):1173-82. (PMID: 11137457) Cancer Res. 2012 Oct 1;72(19):5048-59. (PMID: 22875023) Autophagy. 2012 Feb 1;8(2):200-12. (PMID: 22252008) Molecules. 2014 Dec 01;19(12):20091-112. (PMID: 25470276) Nat Cell Biol. 2009 Dec;11(12):1487-95. (PMID: 19935649) J Nat Prod. 1999 Jun;62(6):895-7. (PMID: 10395513) Org Lett. 2020 Nov 6;22(21):8307-8312. (PMID: 33034457) J Biol Chem. 1987 Apr 25;262(12):5592-5. (PMID: 3106339) Nat Rev Cancer. 2008 Oct;8(10):755-68. (PMID: 18784658) Org Lett. 2006 May 11;8(10):2039-42. (PMID: 16671776) Chemistry. 2013 Apr 22;19(17):5476-86. (PMID: 23447120) Mol Cancer Ther. 2014 Jul;13(7):1758-71. (PMID: 24785258) Nat Rev Drug Discov. 2014 Jul;13(7):497-512. (PMID: 24981363) Nutr Cancer. 2021;73(8):1471-1479. (PMID: 32705888) Nat Rev Clin Oncol. 2015 Aug;12(8):445-64. (PMID: 25850553) Colloids Surf B Biointerfaces. 2021 Jun;202:111702. (PMID: 33780906) J Biol Chem. 1992 Aug 5;267(22):15511-5. (PMID: 1639791) J Am Chem Soc. 1946 Jul;68:1204-8. (PMID: 20990951) Chemosphere. 2016 Jul;154:204-214. (PMID: 27058912) Cancer Res. 2005 Aug 1;65(15):6934-42. (PMID: 16061678) EXCLI J. 2020 Aug 05;19:1120-1123. (PMID: 33088249) Int J Oncol. 2018 Jan;52(1):67-76. (PMID: 29138806) Invest New Drugs. 2014 Apr;32(2):243-9. (PMID: 23645447) Angew Chem Int Ed Engl. 2020 Jan 20;59(4):1532-1536. (PMID: 31693792) Nat Rev Drug Discov. 2021 Jul;20(7):509-530. (PMID: 33742187) Pharm Res. 2011 Apr;28(4):827-38. (PMID: 21161336) Cancer Res. 2006 Nov 1;66(21):10553-9. (PMID: 17079479) Mol Cell Oncol. 2014 Jul 15;1(1):e29911. (PMID: 27308318) Cancer Res. 2007 Jan 15;67(2):573-9. (PMID: 17234765) Chem Commun (Camb). 2013 Nov 4;49(85):9944-6. (PMID: 24037337) Front Oncol. 2020 Mar 13;10:311. (PMID: 32232002) Autophagy. 2019 Jul;15(7):1258-1279. (PMID: 30786811) Int Immunopharmacol. 2020 Nov;88:106991. (PMID: 33182071) PLoS One. 2008 Aug 06;3(8):e2888. (PMID: 18682804) Cell Rep. 2017 Dec 19;21(12):3498-3513. (PMID: 29262329) Chemistry. 2020 Jun 10;26(33):7416-7424. (PMID: 32083773) Chin J Cancer. 2010 Mar;29(3):254-60. (PMID: 20193106) Hepatology. 2006 Jul;44(1):240-51. (PMID: 16799977) Int J Oncol. 2000 Feb;16(2):333-8. (PMID: 10639578) Drug Discov Ther. 2009 Dec;3(6):243-6. (PMID: 22495656) Gastroenterology. 2002 Dec;123(6):1941-8. (PMID: 12454851) Anticancer Drugs. 1996 Sep;7(7):745-51. (PMID: 8949985) Nature. 2006 Dec 21;444(7122):1083-7. (PMID: 17183323) J Cell Mol Med. 2020 Oct;24(20):11667-11679. (PMID: 32935427) Nat Cell Biol. 2014 Jun;16(6):488-94. (PMID: 24875735) Stem Cell Investig. 2018 Mar 12;5:5. (PMID: 29682512) Cancer Sci. 2012 Apr;103(4):684-90. (PMID: 22192169) Biomed Pharmacother. 2018 Nov;107:484-494. (PMID: 30107344) Int J Cancer. 2018 Mar 1;142(5):999-1009. (PMID: 29047105) Nature. 1994 Feb 17;367(6464):645-8. (PMID: 7509044) Drug Discov Today. 2014 Oct;19(10):1547-62. (PMID: 24819719) ChemMedChem. 2020 Jan 17;15(2):236-246. (PMID: 31702860) Oncogene. 2016 Apr 28;35(17):2197-207. (PMID: 26257057) Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12682-7. (PMID: 15314234) Clin Cancer Res. 2006 Feb 15;12(4):1074-9. (PMID: 16489059) Eur J Cancer. 1994;30A(11):1675-82. (PMID: 7833143) Mol Cell Endocrinol. 1993 Dec;98(1):17-25. (PMID: 8143910) World J Stem Cells. 2015 Oct 26;7(9):1185-201. (PMID: 26516409) J Antibiot (Tokyo). 1974 Nov;27(11):814-21. (PMID: 4452657) Nature. 2001 Nov 1;414(6859):105-11. (PMID: 11689955) Cancer Lett. 2012 Oct 1;323(1):48-57. (PMID: 22484470) Cell Res. 2012 Jan;22(1):248-58. (PMID: 21727908) J Mol Signal. 2011 Jul 20;6:7. (PMID: 21774804) PLoS One. 2015 Aug 25;10(8):e0136694. (PMID: 26305906) Mol Carcinog. 2006 May;45(5):320-32. (PMID: 16526022) Apoptosis. 2006 Jun;11(6):943-53. (PMID: 16547587) Cancer Res. 2007 Apr 15;67(8):3716-24. (PMID: 17440084) Oncogene. 2019 Nov;38(46):7181-7195. (PMID: 31417187) Nat Commun. 2017 Jun 12;8:15773. (PMID: 28604738) Pathol Res Pract. 2015 Aug;211(8):557-69. (PMID: 26092594) Cell. 2011 Aug 19;146(4):633-44. (PMID: 21854987) Elife. 2016 Jul 12;5:. (PMID: 27403889) J Biol Chem. 2008 Mar 21;283(12):8046-54. (PMID: 18182388) Oncogene. 2018 Aug;37(32):4358-4371. (PMID: 29717263) Tumour Biol. 2017 Mar;39(3):1010428317695035. (PMID: 28349817) J Cell Biol. 2007 Feb 26;176(5):565-71. (PMID: 17312023) Nat Chem Biol. 2009 Feb;5(2):100-7. (PMID: 19125156) Front Oncol. 2020 Jul 17;10:1138. (PMID: 32766148) Curr Med Chem. 2021;28(22):4321-4342. (PMID: 32107991) Cell Cycle. 2012 Jul 15;11(14):2691-8. (PMID: 22732500) Nature. 2014 Sep 25;513(7519):481-3. (PMID: 25254460) Stem Cells. 2014 Sep;32(9):2309-23. (PMID: 24809620) Cancer Res. 2006 Apr 1;66(7):3347-50. (PMID: 16585150) Cancer Discov. 2012 May;2(5):405-13. (PMID: 22588878) Parasitol Res. 2005 Apr;96(1):49-56. (PMID: 15772867) Nature. 2007 Jan 4;445(7123):106-10. (PMID: 17122772) Drug Des Devel Ther. 2020 Aug 11;14:3235-3249. (PMID: 32884235) Cancer Res. 2016 Aug 1;76(15):4457-69. (PMID: 27302166) Cell Death Dis. 2013 Mar 28;4:e561. (PMID: 23538442) J Clin Invest. 2018 Jun 1;128(6):2376-2388. (PMID: 29708513) Nat Rev Genet. 2013 Mar;14(3):204-20. (PMID: 23400093) Oncotarget. 2017 Sep 15;8(60):101112-101129. (PMID: 29254150) J Cancer Res Clin Oncol. 2009 Oct;135(10):1369-76. (PMID: 19340456) Int J Oncol. 2017 Mar;50(3):773-786. (PMID: 28112374) J Am Chem Soc. 1986 Sep 1;108(19):6048-50. (PMID: 22175376) Oncotarget. 2017 Nov 21;8(65):108498-108508. (PMID: 29312546) Oncol Rep. 2019 Jul;42(1):425-435. (PMID: 31180522) Life Sci. 2000 Jul 7;67(7):733-42. (PMID: 10968403) Cancer Chemother Pharmacol. 2019 Sep;84(3):591-598. (PMID: 31203390) Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):16062-7. (PMID: 21900605) Transl Oncol. 2009 Dec;2(4):321-8. (PMID: 19956394) Environ Toxicol. 2021 Jun;36(6):1135-1142. (PMID: 33539684) Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20224-9. (PMID: 24277854) Biochem Biophys Res Commun. 2018 Feb 26;497(1):241-247. (PMID: 29428725) Br J Pharmacol. 2012 Sep;167(1):48-66. (PMID: 22506590) Toxicol Lett. 2015 Jun 15;235(3):189-98. (PMID: 25865432) Drug Des Devel Ther. 2018 May 04;12:1119-1133. (PMID: 29765202) Gastroenterology. 2014 Dec;147(6):1393-404. (PMID: 25181692) Plant Physiol. 1998 Nov;118(3):965-73. (PMID: 9808741) Nat Rev Cancer. 2009 Apr;9(4):265-73. (PMID: 19262571) Mar Drugs. 2017 Jul 18;15(7):. (PMID: 28718836) Annu Rev Med. 2002;53:615-27. (PMID: 11818492) Cancer Sci. 2014 Sep;105(9):1087-92. (PMID: 24975284) Nature. 2015 Sep 10;525(7568):256-60. (PMID: 26331542) Int J Oncol. 2018 Feb;52(2):579-588. (PMID: 29207190) Cell. 2016 Jun 30;166(1):21-45. (PMID: 27368099) Med Chem. 2011 Mar;7(2):106-11. (PMID: 21222617) J Clin Invest. 2011 Jul;121(7):2723-35. (PMID: 21633165) Biochim Biophys Acta. 2016 Nov;1860(11 Pt A):2484-2497. (PMID: 27474203) Ther Adv Med Oncol. 2019 May 08;11:1758835919846375. (PMID: 31156720) Genet Mol Res. 2015 Apr 13;14(2):3355-61. (PMID: 25966102) Nat Rev Cancer. 2018 Jul;18(7):452-464. (PMID: 29643473) Biochem Pharmacol. 1990 Jan 1;39(1):187-93. (PMID: 2153378) Clin Cancer Res. 2001 Dec;7(12):4174-81. (PMID: 11751518) Nat Rev Cancer. 2010 Feb;10(2):147-56. (PMID: 20075923) Science. 1983 Aug 26;221(4613):823-8. (PMID: 6308762) Oncogene. 2019 Feb;38(6):780-793. (PMID: 30181548) J Biol Chem. 2018 Aug 24;293(34):13059-13072. (PMID: 29907569) Bioorg Med Chem. 1996 Apr;4(4):531-6. (PMID: 8735840) Ecotoxicol Environ Saf. 2021 Jan 15;208:111693. (PMID: 33396024) Clin Epigenetics. 2014 Oct 13;6(1):20. (PMID: 25478034) Acta Biochim Biophys Sin (Shanghai). 2019 Dec 13;51(12):1267-1275. (PMID: 31750892) Sci Rep. 2016 Jan 27;6:19874. (PMID: 26813495) Mycoscience. 2021 Jan 20;62(1):64-70. (PMID: 37090018) Int J Cancer. 2011 Feb 15;128(4):951-61. (PMID: 20473900) Clin Cancer Res. 2002 Jul;8(7):2369-77. (PMID: 12114442) Clin Exp Metastasis. 2011 Dec;28(8):751-63. (PMID: 21750907) Int J Oncol. 2016 May;48(5):2175-83. (PMID: 26983360) J Nat Med. 2021 Jun;75(3):590-601. (PMID: 33713277) J Agric Food Chem. 2019 Feb 13;67(6):1666-1673. (PMID: 30629413) Anticancer Agents Med Chem. 2015;15(5):605-15. (PMID: 25584696) Cancer Lett. 2016 Jul 1;376(2):249-58. (PMID: 27060208) Chem Biol. 2014 Sep 18;21(9):1196-210. (PMID: 25237863) Int J Nanomedicine. 2012;7:4487-97. (PMID: 22927762) Br J Cancer. 2010 Apr 13;102(8):1276-83. (PMID: 20354527) PLoS One. 2016 Dec 14;11(12):e0168170. (PMID: 27973612) Oncogene. 2017 Jan 19;36(3):373-386. (PMID: 27270440) Oncogene. 2008 Sep 1;27(38):5124-31. (PMID: 18758481) J Cell Physiol. 2017 Oct;232(10):2818-2828. (PMID: 27861885) J Exp Clin Cancer Res. 2019 Jan 15;38(1):19. (PMID: 30646963) Dev Dyn. 2005 Jul;233(3):706-20. (PMID: 15937929) Gastroenterology. 2011 Jul;141(1):279-91, 291.e1-5. (PMID: 21640118) Phytomedicine. 2019 Jan;52:117-128. (PMID: 30599890) |
| معلومات مُعتمدة: | R15 GM146188 United States GM NIGMS NIH HHS; R35 GM134910 United States GM NIGMS NIH HHS |
| تواريخ الأحداث: | Date Created: 20230427 Date Completed: 20230817 Latest Revision: 20240817 |
| رمز التحديث: | 20240817 |
| مُعرف محوري في PubMed: | PMC10524555 |
| DOI: | 10.1039/d3np00002h |
| PMID: | 37103550 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1460-4752 |
|---|---|
| DOI: | 10.1039/d3np00002h |